Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THETIS: ATL001 in Metastatic or Recurrent Melanoma
NCT03997474Phase 2Terminated
- Sponsor
- Achilles Therapeutics plc
- Start
- Aug 2019
- Primary completion
- Sep 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Native Immune Cells
- Countries
- 2
01
Overview
A Phase 2 trial of ATL001 in melanoma, sponsored by Achilles Therapeutics plc. Started Aug 2019; status: terminated.
02
Drugs
ATL001
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03997474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03997474.